Skip to content

A randomized controlled trial for the effect of Ba-Bao-Dan on liver function after hepatectomy

A randomized controlled trial for the effect of Ba-Bao-Dan on liver function after hepatectomy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031455
Enrollment
Unknown
Registered
2020-04-01
Start date
2020-03-31
Completion date
Unknown
Last updated
2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic insufficiency

Interventions

Test group:Basic liver protection therapy + Babaodan capsule
control group:Basic liver protection therapy

Sponsors

Shanghai Public Health Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The patient receive hepatectomy and met the following conditions: (1) Aged 18-70 years old; (2) On the first day after operation, the child Pugh score of liver function was grade A or B; (3) More than one segment of liver was resected. 2. If the patient has malignant tumor, R0 resection is needed; 3. Patients without infection and no record of using antibiotics before operation; 4. Patients who can drink water and take medicine from the first day after operation.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to babaodan and its similar drugs or have obvious gastrointestinal reactions after taking the medicine; 2. The child Pugh score of liver function was grade C on the first day after operation; 3. Patients who had a history of esophageal variceal bleeding before operation; 4. Patients with severe hypertension, diabetes, kidney disease, heart failure and other basic diseases; 5. Pregnant women; 6. Patients with infection of biliary system, abdominal cavity, lung, urinary system, etc. who need antibiotics before operation; 7. Patients with active immune liver disease.

Design outcomes

Primary

MeasureTime frame
total bilirubin;albumin;PT;ascites;hepatic encephalopathy;

Secondary

MeasureTime frame
ALT;AST;

Countries

China

Contacts

Public ContactLi Yesheng

Shanghai Public Health Clinical Center

leeyesheng@163.com+86 21-37990333-6339

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026